MarketCap
Charles River Laboratories International CRL
$ 338.13
8.19%
Facebook
X
Telegram
Charles River Laboratories International Total Current Liabilities | CRL
Annual Total Current Liabilities Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 B | 994 M | 1.06 B | 1.09 B | 1.03 B | 840 M | 710 M | 558 M | 464 M | 430 M | 312 M | 296 M | 247 M | 342 M | 217 M | 260 M | 250 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 217 M | 601 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M |  USA |
 |
ICON Public Limited Company
ICLR
|
3.2 B | $ 204.67 | 1.5 % | $ 16.1 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
3.54 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
247 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
9.32 M | $ 2.4 | -11.93 % | $ 9.56 M |  Israel |
 |
Myriad Genetics
MYGN
|
134 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
751 K | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
88.3 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
147 M | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
158 M | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
3.75 M | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
39.6 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
250 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
 |
Quidel Corporation
QDEL
|
337 M | $ 10.69 | -16.78 % | $ 450 M | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | China |
 |
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
36.6 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
91.4 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
2.78 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.55 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
1.33 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
6.81 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.15 B | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
1.58 B | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
31.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.2 B | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
441 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
512 M | $ 50.36 | -0.98 % | $ 10.9 B |  Niderland |
 |
RadNet
RDNT
|
587 M | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
24.3 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
56.2 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
30.5 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
15.2 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |